Management of Menopausal Symptoms Following Gynaecological Cancer
Interactive clinical decision tool based on the official joint guidelines of the British Gynaecological Cancer Society (BGCS) and British Menopause Society (BMS).
🚦 Official BMS/BGCS Traffic Light Classification
British Gynaecological Cancer Society 2024Suitable for routine non-specialist and primary care use.
Individualized discussion with patient. Consider specialist / MDT advice.
HRT not recommended. Refer for specialist advice only if non-hormonal approaches fail.
Primary Tumor Site
Select organ
Histological Subtype & Stage
Select clinical subgroup
Select primary tumor site above first...
Awaiting clinical selection
Select tumor site and specific subtype on the left to see precise BMS/BGCS 2024 recommendations.
—
Evidence base: British Gynaecological Cancer Society & British Menopause Society (August 2024)
Key Principles for Type of HRT Selection (BMS / BGCS 2024 Consensus)
Following hysterectomy: Estrogen-only HRT. Exception: personal history of endometriosis requires continuous combined HRT to prevent reactivation of residual endometriotic implants.
Uterus still in situ (including after radiotherapy for cervical cancer or endometrial ablation): Strictly continuous combined HRT. Progestogen dose must be proportionate to estrogen dose for endometrial protection.
Transdermal estradiol is the preferred choice for women with metabolic syndrome, obesity, risk factors for venous thromboembolism (VTE) or stroke (Grade A).
Evidence-based non-hormonal approaches for vasomotor symptoms include prescription pharmacological classes — serotonin-norepinephrine reuptake inhibitors (SNRIs/SSRIs), gabapentinoids, neurokinin-3 receptor antagonists (NK3R), alongside non-pharmacological modalities (cognitive behavioral therapy, lifestyle modifications). Specific agent selection, dose titration, and treatment duration must be determined individually by the treating clinician in full accordance with authorized prescribing information and the patient comorbidity profile.
Official Clinical Evidence & Primary Sources
BMS & BGCS Joint Guideline (2024)
Management of menopausal symptoms following treatment of gynaecological cancer: BMS & BGCS Guideline (Table 1, Page 26 consensus).
BGCS.org.uk Full PDF Document
Official unabridged consensus publication directly hosted on the British Gynaecological Cancer Society repository (30-page PDF).
Ministry of Health of Kazakhstan (NRCHD)
Official national repository of authorized clinical diagnostic and treatment protocols of the Ministry of Health of the Republic of Kazakhstan.